Immunovant
Chedvi Levin-Sister is Vice President of SEC Reporting, Technical Accounting and Tax at Immunovant. Prior to joining Immunovant, Chedvi spent over 15 years at PwC where she held numerous roles, most recently as Assurance Director, serving a range of industries and global clients including large pharmaceutical organizations, life science, medical device, SEC registrant, technology and start-up companies.
Chedvi’s expertise includes regulatory compliance of PCAOB, US GAAP, US GAAS, SEC and IFRS, technical and income tax accounting, revenue recognition (inclusive of Gross-to-net in domestic US Pharmaceutical companies), stock-based compensation and leases; she has deep transactional experience in carve-out and business combinations along with implementation of internal controls over financial reporting and remediation of material weaknesses.
Chedvi earned a B.A (cum laude) from The Jerusalem College of Technology (JCT), Israel, in 2005, in Management Accounting (Major) and Information System (Minor); she is a CPA (Isr.)
Immunovant
6 followers
Immunovant, Inc. is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases. Immunovant is developing IMVT-1401, a novel, fully human anti-FcRn monoclonal antibody, as a subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies.